Skip to main content
NACFC 2025 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Session includes an in person invitee/speaker with CF
Session includes an in person invitee/speaker with CF
Livestreamed Session
Livestreamed Session
Recorded Session
Recorded Session
Session is Ticketed (Must Register for Session through Registration)
Session is Ticketed (Must Register for Session through Registration)
Food Available for Session Attendees
Food Available for Session Attendees
Session Feedback

CLIN
Session Type: Workshop

W32--Lung Health in CF | Room: 433-434

Saturday, October 25, 2025
10:15 AM - 12:15 PM PDT
Location:433-434

Recorded Session

This session will explore state-of-the-art clinical trials and investigator lead studies focusing on lung health and pulmonary outcomes in people with CF. This work will cover all ages of people with CF from all over the world and encompass real-life challenges in the elexacaftor/tezacaftor/ivacaftor (ETI) era of CF care. Experts will present recent data on microbiome changes from the STOP2 trial as well as CF STORM, presenting crucial pulmonary outcomes in expansive clinical trials. Changes in ETI care, practical dosing and cessation of modulator therapy, and prolonged outcomes from the PROMISE study will also be discussed, emphasizing how ETI has impacted pulmonary health in the current health care setting. Finally, experts will present compelling data and findings in people with CF during pregnancy, exploring a milestone thought to be rare and unlikely for the CF community decades ago.

Learning Objectives:

  • Understand state of the art lung health outcomes in the ETI era
  • Understand up to date pulmonary exacaerbation and microbiome outcomes in people with CF across all ages
  • Understand real time challenges, clinical scenarios, and shifts in lung health management for people with CF

Presentations:

  • 10:15 AM - 12:15 PM PDT
    W32.1- Long term clinical effectiveness of elexacaftor/tezacaftor/ivacaftor (ETI) through 4.5 years of ETI therapy: PROMISE Cohort

    Speaker: George M. Solomon, MD – University of Alabama at Birmingham

  • 10:15 AM - 12:15 PM PDT
    W32.2- Registry-based RCT to assess change in respiratory function for people with CF established on elexacaftor/tezacaftor/ivacaftor after withdrawal of nebulised mucoactive therapies: CF STORM

    Speaker: Gwyneth Davies, MBChB PhD – UCL Great Ormond Street Institute of Child Health

  • 10:15 AM - 12:15 PM PDT
    W32.3- Impact of gaps in ETI treatment in adults with CF

    Speaker: Alexander Pichler, n/a – University of Washington

  • 10:15 AM - 12:15 PM PDT
    W32.4- A Cystic Fibrosis Foundation Patient Registry analysis of pulmonary exacerbations and lung function in pregnant versus non-pregnant females with CF

    Speaker: Raksha Jain, MD, MSc – University of Texas Southwestern Medical Center

  • 10:15 AM - 12:15 PM PDT
    W32.5- Lung microbiome and clinical outcomes during antibiotic treatment of CF pulmonary exacerbations: Insights from the STOP2 trial

    Speaker: Lindsay J. Caverly, MD – University of Michigan Medical School